Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Akkerstor
- Development stage
- Unknown
- Lead developer
- Blue Heron Pharmaceuticals
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Akkerstor is a probiotic/postbiotic product developed by Blue Heron Pharmaceuticals, featuring a proprietary strain of *Akkermansia muciniphila*. This bacterium is a key member of the gut microbiota that colonizes the mucosal layer of the gastrointestinal tract. Akkerstor is primarily aimed at improving metabolic health, addressing conditions such as obesity, insulin resistance, and systemic inflammation. Its mechanism of action involves the reinforcement of the intestinal barrier, which reduces the translocation of pro-inflammatory lipopolysaccharides (LPS) into the bloodstream (metabolic endotoxemia). Specifically, the outer membrane protein Amuc_1100 of *A. muciniphila* has been shown to interact with Toll-like receptor 2 (TLR2), enhancing tight junction expression. The product is typically provided in a pasteurized (heat-killed) form, which has been found in clinical studies to be as effective as, or more effective than, the live bacterium in improving metabolic parameters.
- Brand names
- Akkerstor
- Other names
- Akkermansia muciniphila probioticPasteurized Akkermansia muciniphila
02
Targets
Beyond the preview
Go deeper on Akkerstor.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Akkerstor.